CancerDrs Find care

Prostate Cancer clinical trials

300 actively recruiting prostate cancer trials in the United States. The most common cancer in men in the U.S. Trials test hormonal, radiation, surgical, and novel therapies across risk groups.

Data from ClinicalTrials.gov · last refreshed · Prostate Cancer stats on SEER

45
Phase 1
115
Phase 2
21
Phase 3
5
Phase 4
114
Other

Prostate Cancer by the numbers (U.S.)

313,780
Estimated new cases (2025)
35,770
Estimated deaths (2025)
97.9%
5-year relative survival
68
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse prostate cancer trials by state

California 101 New York 87 Texas 72 Florida 59 Massachusetts 46 Maryland 41 Pennsylvania 41 Illinois 40 Ohio 37 Virginia 36 Michigan 35 Washington 34 Minnesota 33 South Carolina 33 Arizona 32 Tennessee 32 Colorado 31 Wisconsin 31 Missouri 28 North Carolina 28 New Jersey 25 Nebraska 24 Oregon 23 Connecticut 21 Georgia 19 Indiana 18 Utah 18 Oklahoma 16 Kansas 15 Louisiana 14 District of Columbia 12 Iowa 12 Kentucky 12 Arkansas 11 Rhode Island 10 Montana 9 Nevada 8 South Dakota 8 Alabama 7 Delaware 7 North Dakota 7 New Hampshire 5 New Mexico 5 West Virginia 5 Idaho 4 Maine 4 Alaska 3 Wyoming 3 Hawaii 2 Vermont 2 Mississippi 1

Top trials by phase + site coverage

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
  • Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama

+ 385 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…

Sponsor: NRG Oncology
NCT ID: NCT04134260
Locations:
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
  • Kaiser Permanente-Anaheim — Anaheim, California

+ 342 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Locations:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • Kaiser Permanente Dublin — Dublin, California

+ 174 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Sponsor: AstraZeneca
NCT ID: NCT06120491
Locations:
  • Research Site — Chandler, Arizona
  • Research Site — Gilbert, Arizona
  • Research Site — Phoenix, Arizona

+ 115 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …

Sponsor: Pfizer
NCT ID: NCT07028853
Locations:
  • Clearview Cancer Institute (Crestwood) — Huntsville, Alabama
  • Clearview Cancer Institute — Huntsville, Alabama
  • Ironwood Cancer & Research Centers — Chandler, Arizona

+ 80 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Locations:
  • University of California at San Diego — La Jolla, California
  • Ronald Reagan UCLA Medical Center — Los Angeles, California
  • Rocky Mountain Cancer Centers — Aurora, Colorado

+ 44 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Sponsor: Curium US LLC
NCT ID: NCT06235151
Locations:
  • Arkansas Urology — Little Rock, Arkansas
  • Providence Medical Foundation — Fullerton, California
  • Tower Urology — Los Angeles, California

+ 40 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).

Sponsor: Amgen
NCT ID: NCT06691984
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • City of Hope National Medical Center — Duarte, California
  • Providence Saint Jude Medical Center — Fullerton, California

+ 39 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Locations:
  • Arizona Clinical Trials — Chandler, Arizona
  • Arkansas Urology — Little Rock, Arkansas
  • University Of California San Diego — La Jolla, California

+ 29 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06970847
Locations:
  • East Valley Urology Center of Arizona — Mesa, Arizona
  • Arkansas Urology Research Center — Little Rock, Arkansas
  • UC Irvine — Irvine, California

+ 21 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Locations:
  • Sansum Clinic — Santa Barbara, California
  • Rocky Mountain Cancer Centers — Denver, Colorado
  • Miami Cancer Institute at Bapt — Miami, Florida

+ 12 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Locations:
  • VA Greater LA Healthcare System — Los Angeles, California
  • Stanford University Medical Center — Palo Alto, California
  • University Cancer and Blood Center LLC — Athens, Georgia

+ 11 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20